AU2009297091B2 - Compositions and methods for achieving sustained therapeutic drug concentrations in a subject - Google Patents
Compositions and methods for achieving sustained therapeutic drug concentrations in a subject Download PDFInfo
- Publication number
- AU2009297091B2 AU2009297091B2 AU2009297091A AU2009297091A AU2009297091B2 AU 2009297091 B2 AU2009297091 B2 AU 2009297091B2 AU 2009297091 A AU2009297091 A AU 2009297091A AU 2009297091 A AU2009297091 A AU 2009297091A AU 2009297091 B2 AU2009297091 B2 AU 2009297091B2
- Authority
- AU
- Australia
- Prior art keywords
- days
- administering
- prodrug
- once
- irinotecan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9951608P | 2008-09-23 | 2008-09-23 | |
| US61/099,516 | 2008-09-23 | ||
| US10693108P | 2008-10-20 | 2008-10-20 | |
| US61/106,931 | 2008-10-20 | ||
| US17343309P | 2009-04-28 | 2009-04-28 | |
| US61/173,433 | 2009-04-28 | ||
| PCT/US2009/005284 WO2010036335A1 (en) | 2008-09-23 | 2009-09-23 | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009297091A1 AU2009297091A1 (en) | 2010-04-01 |
| AU2009297091B2 true AU2009297091B2 (en) | 2015-03-05 |
Family
ID=41268391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009297091A Active AU2009297091B2 (en) | 2008-09-23 | 2009-09-23 | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8906353B2 (https=) |
| EP (1) | EP2349346B1 (https=) |
| JP (3) | JP2012503602A (https=) |
| KR (1) | KR20110063457A (https=) |
| CN (1) | CN102164617A (https=) |
| AU (1) | AU2009297091B2 (https=) |
| CA (1) | CA2736939C (https=) |
| CY (1) | CY1122208T1 (https=) |
| DK (1) | DK2349346T3 (https=) |
| ES (1) | ES2744975T3 (https=) |
| HR (1) | HRP20192120T1 (https=) |
| HU (1) | HUE047352T2 (https=) |
| IL (1) | IL211888A (https=) |
| LT (1) | LT2349346T (https=) |
| MX (1) | MX2011003063A (https=) |
| PL (1) | PL2349346T3 (https=) |
| PT (1) | PT2349346T (https=) |
| RS (1) | RS59607B1 (https=) |
| SI (1) | SI2349346T1 (https=) |
| SM (1) | SMT201900609T1 (https=) |
| WO (1) | WO2010036335A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047352T2 (hu) | 2008-09-23 | 2020-04-28 | Nektar Therapeutics | Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal) |
| WO2012137225A1 (en) * | 2011-04-08 | 2012-10-11 | Sphaera Pharma Pvt. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| CN104813167B (zh) * | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| US20160250177A1 (en) * | 2015-02-17 | 2016-09-01 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
| KR102383824B1 (ko) | 2016-06-02 | 2022-04-06 | 이노파막스, 인크. | 암 치료법을 위한 메트로놈 경구 젬시타빈 |
| CN106539557A (zh) * | 2016-10-08 | 2017-03-29 | 西安交通大学 | 一种基于恒速静脉输入的药代动力学参数的测定方法 |
| JP7546552B2 (ja) | 2018-09-17 | 2024-09-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ポリマーベースの高分子プロドラッグ |
| CA3209512A1 (en) * | 2021-02-23 | 2022-09-01 | Edison Oncology | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases |
| CN115317486B (zh) * | 2022-08-17 | 2024-04-19 | 南昌大学 | 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112088A1 (en) * | 2003-09-17 | 2005-05-26 | Xuan Zhao | Multi-arm polymer prodrugs |
| US20070197575A1 (en) * | 2006-02-09 | 2007-08-23 | Hong Zhao | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| CN101199857A (zh) * | 2007-12-12 | 2008-06-18 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| TW438775B (en) | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| DE69735057T2 (de) | 1996-03-12 | 2006-08-31 | PG-TXL Co., L.P., Houston | Wasserlösliche paclitaxel-prodrogen |
| US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| EP1176985A2 (en) | 1999-04-28 | 2002-02-06 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| AU781839B2 (en) | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
| AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| EP1301810B1 (en) | 2000-07-21 | 2008-09-10 | Services Petroliers Schlumberger | Nuclear magnetic resonance methods for extracting information about a fluid in a rock |
| EP1355671A2 (en) | 2000-11-30 | 2003-10-29 | Nektar Therapeutics Al, Corporation | Water-soluble polymer conjugates of triazine derivatives |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7401013B2 (en) | 2001-10-15 | 2008-07-15 | Lockheed Martin Corporation | Method to optimize test data |
| WO2003037384A2 (en) | 2001-10-29 | 2003-05-08 | Nektar Therapeutics Al, Corporation | Polymer conjugates of protein kinase c inhibitors |
| KR20050042013A (ko) | 2001-10-30 | 2005-05-04 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 레티노산의 수용성 중합체 콘쥬게이트 |
| JP2005517648A (ja) * | 2001-12-07 | 2005-06-16 | インターミューン インコーポレイテッド | 肝炎ウイルス感染症を治療するための組成物および方法 |
| US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| CN1668293A (zh) | 2002-06-06 | 2005-09-14 | 华盛顿大学 | 使用青蒿素样化合物预防或延缓癌症显现的方法 |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| BRPI0314042B8 (pt) | 2002-09-06 | 2021-05-25 | Calando Pharmaceuticals Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| EP1989212B1 (en) | 2006-02-17 | 2013-06-19 | Cascade Prodrug Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| WO2008098178A2 (en) * | 2007-02-09 | 2008-08-14 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| HUE047352T2 (hu) | 2008-09-23 | 2020-04-28 | Nektar Therapeutics | Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal) |
-
2009
- 2009-09-23 HU HUE09789364A patent/HUE047352T2/hu unknown
- 2009-09-23 RS RS20191501A patent/RS59607B1/sr unknown
- 2009-09-23 AU AU2009297091A patent/AU2009297091B2/en active Active
- 2009-09-23 US US13/120,551 patent/US8906353B2/en active Active
- 2009-09-23 KR KR1020117005982A patent/KR20110063457A/ko not_active Ceased
- 2009-09-23 DK DK09789364.8T patent/DK2349346T3/da active
- 2009-09-23 WO PCT/US2009/005284 patent/WO2010036335A1/en not_active Ceased
- 2009-09-23 EP EP09789364.8A patent/EP2349346B1/en active Active
- 2009-09-23 JP JP2011527834A patent/JP2012503602A/ja not_active Withdrawn
- 2009-09-23 ES ES09789364T patent/ES2744975T3/es active Active
- 2009-09-23 CN CN2009801371326A patent/CN102164617A/zh active Pending
- 2009-09-23 SI SI200932010T patent/SI2349346T1/sl unknown
- 2009-09-23 LT LTEP09789364.8T patent/LT2349346T/lt unknown
- 2009-09-23 SM SM20190609T patent/SMT201900609T1/it unknown
- 2009-09-23 MX MX2011003063A patent/MX2011003063A/es active IP Right Grant
- 2009-09-23 PL PL09789364T patent/PL2349346T3/pl unknown
- 2009-09-23 PT PT97893648T patent/PT2349346T/pt unknown
- 2009-09-23 HR HRP20192120TT patent/HRP20192120T1/hr unknown
- 2009-09-23 CA CA2736939A patent/CA2736939C/en active Active
-
2011
- 2011-03-23 IL IL211888A patent/IL211888A/en active IP Right Grant
-
2014
- 2014-11-17 JP JP2014232556A patent/JP6076317B2/ja active Active
- 2014-11-26 US US14/555,440 patent/US9801873B2/en active Active
-
2016
- 2016-09-26 JP JP2016186670A patent/JP2016216510A/ja not_active Withdrawn
-
2017
- 2017-10-03 US US15/723,981 patent/US10525051B2/en active Active
-
2019
- 2019-09-17 CY CY20191100970T patent/CY1122208T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112088A1 (en) * | 2003-09-17 | 2005-05-26 | Xuan Zhao | Multi-arm polymer prodrugs |
| US20070197575A1 (en) * | 2006-02-09 | 2007-08-23 | Hong Zhao | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| CN101199857A (zh) * | 2007-12-12 | 2008-06-18 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
Non-Patent Citations (3)
| Title |
|---|
| ALLEGRINI, G. et al: British Journal Of Cancer, Nature Publishing Group, London, GB, vol. 98, no. 8, 1 April 2008, pages 1312-1319 * |
| LALLOO, A. et al: Journal Of Controlled Release, Elsevier, Amsterdam, NL, vol. 112, no. 3, 30 May 2006, pages 333-342 * |
| ROWINSKY, E.K. et al, "A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1- Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies", Journal of Clinical Oncology 2003 (21) 1, pages 148-157. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011003063A (es) | 2011-04-21 |
| EP2349346B1 (en) | 2019-08-28 |
| RS59607B1 (sr) | 2020-01-31 |
| KR20110063457A (ko) | 2011-06-10 |
| HRP20192120T1 (hr) | 2020-02-21 |
| HUE047352T2 (hu) | 2020-04-28 |
| US20150087668A1 (en) | 2015-03-26 |
| US20180028525A1 (en) | 2018-02-01 |
| JP2012503602A (ja) | 2012-02-09 |
| ES2744975T3 (es) | 2020-02-27 |
| EP2349346A1 (en) | 2011-08-03 |
| CY1122208T1 (el) | 2020-11-25 |
| IL211888A (en) | 2015-08-31 |
| SI2349346T1 (sl) | 2019-12-31 |
| US9801873B2 (en) | 2017-10-31 |
| PT2349346T (pt) | 2019-10-24 |
| CA2736939A1 (en) | 2010-04-01 |
| PL2349346T3 (pl) | 2020-03-31 |
| US10525051B2 (en) | 2020-01-07 |
| AU2009297091A1 (en) | 2010-04-01 |
| JP2016216510A (ja) | 2016-12-22 |
| SMT201900609T1 (it) | 2020-01-14 |
| LT2349346T (lt) | 2019-09-25 |
| IL211888A0 (en) | 2011-06-30 |
| CN102164617A (zh) | 2011-08-24 |
| JP6076317B2 (ja) | 2017-02-08 |
| US20110269789A1 (en) | 2011-11-03 |
| WO2010036335A1 (en) | 2010-04-01 |
| JP2015034180A (ja) | 2015-02-19 |
| CA2736939C (en) | 2021-09-14 |
| US8906353B2 (en) | 2014-12-09 |
| DK2349346T3 (da) | 2019-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10525051B2 (en) | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject | |
| Venditto et al. | Cancer therapies utilizing the camptothecins: a review of the in vivo literature | |
| Manjappa et al. | Polymeric mixed micelles: improving the anticancer efficacy of single-copolymer micelles | |
| JP2022166327A (ja) | 癌の治療法 | |
| US20170266293A1 (en) | Methods of treating cancers with therapeutic nanoparticles | |
| US12514853B2 (en) | Therapeutic dendrimer | |
| WO2019204799A1 (en) | Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids | |
| WO2014084378A1 (ja) | 環状ｒｇｄ配列含有ペプチドを含む抗癌剤 | |
| KR101678881B1 (ko) | 부작용을 가지지 않는 항암제 | |
| HK1155083A (en) | Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan) | |
| HK1155083B (en) | Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan) | |
| Dashtipoura et al. | Polymeric micelles in TKIs’ delivery for cancer treatment | |
| Yu et al. | Polylactide-tethered SN38 prodrugs in polymeric nanoparticles as reliable nanomedicines for the treatment of cervical cancer | |
| AU2013205079B2 (en) | Treatment of cancer | |
| Connolly et al. | An overview of DNA topoisomerase I inhibitors under development | |
| HK1214145B (en) | Anticancer agent having no side effects | |
| Van Cuong et al. | Chemotherapy of Nano-Sized Camptothecin-Derived Drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |